Press Releases June 17, 2026 08:00 AM

electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference

electroCore to present at iAccess Alpha Virtual Best Ideas Summer Investment Conference in June 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
ECOR

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference scheduled for June 23-24, 2026. Interim President and CFO Joshua Lev will present and meet with investors. The company focuses on non-invasive bioelectronic technologies for health and wellness, including prescription products treating chronic pain and wellness devices.

electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
ECOR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • electroCore will present at a leading virtual investment conference on June 23, 2026.
  • The presentation will be led by Interim President and CFO Joshua Lev, highlighting corporate developments.
  • The company specializes in non-invasive bioelectronic treatments for chronic pain and wellness products, positioning it within healthcare and biotech sectors.

ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. Joshua Lev, Interim President and Chief Financial Officer, will deliver a presentation and host one-on-one investor meetings during the conference.

iAccess Alpha Virtual Best Ideas Summer Investment Conference

Dates: June 23-24, 2026
Presentation Time: Tuesday, June 23 at 1:30 p.m. ET
Webcast: https://www.webcaster5.com/Webcast/Page/3165/54084

For more information about the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, or to register and schedule a one-on-one meeting with management, please visit the conference website at https://www.iaccessalpha.com.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
[email protected]


Risks

  • Market acceptance and commercial adoption of electroCore’s bioelectronic technologies remain uncertain, impacting potential revenue growth.
  • Relying on a virtual conference for investor engagement may limit the effectiveness of communication compared to in-person events.
  • The bioelectronic medicine sector faces technological and regulatory challenges that could affect product commercialization and future developments.

More from Press Releases

Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Sep 15, 2026 INNSUITES ANNOUNCES 2027 FISCAL FIRST HALF $4M RECORD REVENUES; REVERSE MERGER INTEREST INCREASES Sep 15, 2026 Apollo Provides $585 Million Financing to The Executive Centre Sep 15, 2026 TTM Technologies, Inc. to Exhibit at electronica India 2026 Trade Fair in Bangalore, Showcasing Leading Advanced Interconnect Solutions and Integrated Systems Sep 15, 2026 Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical Sep 15, 2026